English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Following the publication of this article, an interested reader drew to our attention that Figs. 3B and 4B contained histological data which had previously been published in Figs. 3B and 4B, respectively, of the following article: Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D and Bader AG: Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 15: 5923-5930, 2010. We have tried to contact the authors of the above paper on several occasions for comment, but without success; therefore, the Editorial Board of the International Journal of Molecular Medicine has taken the decision to retract this publication. We thank the reader for drawing this matter to our attention. [the original article was published in the International Journal of Molecular Medicine 35: 1369-1373, 2015; DOI: 10.3892/ijmm.2015.2147].

Systemic delivery of synthetic microRNA-451 is an effective therapeutic strategy for the treatment of lung cancer